SignalCorporate
Pfizer raises 2026 outlook to $62B-$64B revenue and $2.95-$3.05 adjusted EPS, targeting high single-digit revenue CAGR from 2028-2033
Pfizer raised 2026 revenue and EPS guidance and set 2028-2033 CAGR target.
Context
What happened: Pfizer raised its 2026 outlook to $62B-$64B in revenue and $2.95-$3.05 in adjusted EPS, and said it targets a high single-digit revenue CAGR from 2028 to 2033.
Key numbers: 2026 revenue outlook $62B-$64B. 2026 adjusted EPS outlook $2.95-$3.05. High single-digit revenue CAGR targeted for 2028-2033. 32% operational revenue growth in the quarter for launch and acquired products.
Why it matters: CEO Albert Bourla cited commercial execution and the 32% operational growth in launch and acquired products as showing the underlying strength of the business.
Coverage: 3 outlets in 24h
What changed
Pfizer raised its 2026 outlook to $62B-$64B in revenue and $2.95-$3.05 in adjusted EPS, and said it targets a high single-digit revenue CAGR from 2028 to 2033.
Why it matters
CEO Albert Bourla cited commercial execution and the 32% operational growth in launch and acquired products as showing the underlying strength of the business.